

Molecular Biology of the two Less Common Vascular Brain Neoplasms in Adults – A Comprehensive Review

Nikolaos Andreas Chrysanthakopoulos ^{1*}, Vassiliki Vazintari ²

¹Dental Surgeon (DDSc),

-Oncologist (MSc), Specialized in Clinical Oncology, Cytology and Histopathology, Dept. of Pathological Anatomy, Medical School, University of Athens, Athens, Greece.

-Resident in Maxillofacial and Oral Surgery, 401 General Military Hospital of Athens, Athens, Greece.

-PhD in Oncology (cand).

-Registrar in Dentistry, NHS of Greece.

²MD, Registrar in Pathology, Ilioupoli Health Centre - NHS of Greece, Athens, Greece.

***Corresponding Author:** Nikolaos Andreas Chrysanthakopoulos, Dental Surgeon (DDSc), Oncologist (MSc), Specialized in Clinical Oncology, Cytology and Histopathology, Dept. of Pathological Anatomy, Medical School, University of Athens, Athens, Greece. Resident in Maxillofacial and Oral Surgery, 401 General Military Hospital of Athens, Athens, Greece. PhD in Oncology (cand). Registrar in Dentistry, NHS of Greece.

Received Date: 09 January 2026 | **Accepted Date:** 13 February 2026 | **Published Date:** 09 March 2026

Citation: Nikolaos A. Chrysanthakopoulos, Vassiliki Vazintari, (2026), Molecular Biology of the two Less Common Vascular Brain Neoplasms in Adults – A Comprehensive Review, *J. Brain and Neurological Disorders*, 9(2): DOI:10.31579/2642-973X/168.

Copyright: © 2026, Nikolaos Andreas Chrysanthakopoulos. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Brain neoplasms are a significant cause of morbidity and mortality worldwide, affecting individuals across an extensive range of demographics. In adults, the most common primary intracranial tumors are gliomas, whereas less common vascular brain neoplasms include hemangioblastomas (HBs) and primary central nervous system lymphomas (PCNSLs). HB is a highly vascular tumor comprising 3% of all Central Nervous System (CNS) tumors. Approximately 25% of these cases are hereditary, resulting from von Hippel-Lindau (VHL) disease - an autosomal dominant disorder - whereas the remainder develop sporadically. These tumors are characterized by a remarkably high prevalence of recurrent somatic mutations (50%) and Loss of Heterozygosity (LOH) at the gene locus on chromosome 3p (72%). Mutations in ARID1B have also been revealed in HB cases. PCNSL is typically a diffuse large B-cell lymphoma (DLBCL). Several genomic alterations have been detected, including the expression of BCL2 and BCL6, mutations in genes encoding p53, ATM, and MYD88, as well as chromosomal deletions, repeated losses, and insertions. Its molecular biology remains a complex field where basic research is essential to meet clinical expectations regarding antitumor efficacy. Modern investigations have focused on understanding the biology and pathogenesis of these tumors to develop new agents for personalized, targeted molecular treatment. The current study presents a comprehensive review of contemporary knowledge regarding the molecular features of these neoplasms. It focuses on the primary intracellular signaling pathways involved in their pathogenesis, genomic and epigenetic characteristics, and the predictive value of molecular indices according to the 2021 WHO classification.

Key Words: brain neoplasms; hemangioblastoma; primary central nervous system; lymphoma; molecular biology; genetics; epigenetics

Introduction

Brain neoplasms affect a wide diversity of individuals and result in significant morbidity and mortality worldwide. Among these, two less common vascular brain neoplasms in adults are hemangioblastomas (HBs) and primary central nervous system lymphomas (PCNSLs). PCNSL is typically a diffuse large B-cell lymphoma (DLBCL) [1]. It primarily affects elderly individuals, with a median age of 66-67 years, whereas it is rare in young individuals [2] and infrequent in the pediatric population [3]. PCNSL accounts for less than 5% of all primary brain

tumors and typically affects the brain, spinal cord, leptomeninges, and eyes [4]. The cellular origin remains to be elucidated, as it is unclear whether PCNSL originates within the CNS or is a systemic lymphoma that escapes from the host's immune system to proliferate in the CNS "sanctuary" [5].

Various genomic alterations have been identified in PCNSL, such as the expression of BCL2, BCL6 [6-8], and IRF4/MUM1 [5], as well as non-

synonymous somatic mutations in MYD88, PIM1, and BTG2 [5,9-14]. Non-conservative mutations have also been recorded in the TP53, ATM, PTEN, JAK3, and PIK2CA loci [5,15]. Structural alterations include deletions at chromosomes 6p21 and 6q21-23 [16,17], affecting PRDM1, PTPRK, and A20/TNFAIP3, recurrent chromosomal losses at 9p21 [16], and insertions on chromosome 12q, harboring CDK4, MDM2, STAT6, and GLI1 [16-20], as well as insertions on the long arms of chromosomes 1, 7, and 18 [18].

Other genomic alterations include CARD11 [5,9-13,21] and MALT1 [22] mutations and overexpression. Copy number alterations (CNAs) and translocations on chromosome 9p24, involving the programmed death-ligand 1 (PD-L1) and 2 (PD-L2) loci [23], are frequent. Homozygous loss of HLA class II genes and CDKN2A [24], recurrent BCL6 translocations [25,26], and TBL1XR1 variations [27] are also common. PCNSL biology is mediated by the JAK/STAT signaling pathway [8,23,28,29]. Furthermore, micro-RNAs (mi RNAs) play a critical role, tumor-suppressive miRNAs, such as miR-193b, miR199a, miR-145, and miR-214, are often downregulated [30], whereas miR-17-5p is notably upregulated [30,31].

Epigenetic silencing via DNA hypermethylation has been detected at loci including MGMT, DAPK, and RFC, as well as the CDKN2A (p16 INK4a/p14ARF) locus [32,33], alongside promoter methylation of CDKN1B and RB1 [18,20]. In cases localized to the spleen, TERT promoter mutations are present [34,35]. Inflammatory markers also play a role, as BCA-1 (CXCL-13) is highly expressed [36-38], and Interleukin (IL)-4 signaling may be critical for pathogenesis and progression [8]. HB is a highly vascular, benign tumor accounting for 3% of all CNS tumors, 1-2.5% of all primary intracranial tumors [39], 7-8% of posterior cranial fossa tumors [40], and 7-10% of spinal cord tumors. Its pathology is characterized by neoplastic “stromal” cells embedded within a dense network of vascular channels [41,42]. HBs develop either sporadically or as a manifestation of von Hippel-Lindau (VHL) disease, an autosomal dominant disorder, in approximately 25% of cases [40]. While 75% of HBs are sporadic, the majority of these cases do not carry observable germline VHL alterations. Sporadic cases typically present as solitary lesions, whereas VHL patients tend to develop multiple HBs [43-45].

The histogenesis of HBs remains uncertain. It has been hypothesized that they originate from embryologically arrested “hem angioblast” stem cells [41,46]. Consequently, the WHO classification categorizes HB as a “neoplasm of uncertain histogenesis” [47,48]. These tumors are primarily diploid with few chromosomal abnormalities [49,50]. The presence of VHL mutations has been estimated at 10% to 44% in sporadic HB cases [51]. The frequency of chromosome 3 aneuploidy ranges from 18% to 69% in these sporadic tumors [49,50]. Mutations in the VHL tumor suppressor gene, located on chromosome 3p25.3 appear to play a role in both sporadic and VHL disease-related tumors [52-54], however the genetic factors explaining the clinical heterogeneity of the HBs remain unknown. Despite CNA in a small subset of cases [53], the HBs exome is remarkably simple, lacking additional oncogenic driver mutations [52,54]. HBs are characterized by a notably high prevalence of recurrent somatic mutations (50%) and LOH of the gene locus on chromosome 3p (72%). These genomic alterations are responsible for biallelic VHL inactivation in 47% of cases, and an inactivating alteration in at least one allele in 78% of sporadic HBs [52]. Mutations in the ARID1B gene have also been recorded. This gene acts as a tumor suppressor in various types of cancers [55,56].

Further analysis is needed to determine whether such sub clonal variations are functionally essential in supporting the sporadic development of HBs [57]. Epigenetic alterations in sporadic and VHL-associated HBs were detected through the molecular characterization of the VHL promoter [53], raising the possibility that DNA methylation patterns could lead to the identification of relevant biological subgroups. Over the past decade, notable progress in genomic research has improved the classification and management of brain tumors. However, despite these molecular

advancements, improvements in overall survival rates and quality of life remain suboptimal. This article provides a comprehensive review of the molecular features of HB and PCNSL, focusing on intracellular signaling pathways, genomic and epigenetic characteristics, and their roles in pathogenesis.

PCNS Lymphoma

Epidemiological data and Classification

PCNSL accounts for 4-6% of all extranodal lymphomas, approximately 2% of all CNS tumors, and up to 1% of all lymphomas [58]. Moreover, its overall incidence rate is 0.5 cases per 100,000-person years, representing 3% to 4% of all newly diagnosed intracranial neoplasms [59]. The median age at diagnosis is 65 years old. The tumor is frequently detected in individuals with acquired immune deficiencies, such as AIDS or post-transplant conditions in immuno-compromised patients, in which the tumor cells are typically Epstein-Barr virus (EBV)-positive [60]. It is also associated with congenital immune deficiencies, such as X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome, or ataxia telangiectasia [61]. Approximately 90% of PCNSL cases are diffuse large B cell lymphomas (DLBCLs), and their immunohistochemical analysis typically demonstrates a non-germinal center B-cell-like (non-GCB) immunophenotype [62-64]. In contrast, a small subcategory of patients is diagnosed with T-cell, marginal zone, Burkitt, or lymphoblastic lymphomas [65].

According to gene expression profiling, tumor cells are most closely related to late GC (exit) B-cells [6]. Currently, the 2021 WHO Classification categorizes PCNSLs primarily as DLBCL, as previously mentioned, without further grading, in contrast to other common primary brain tumors [1].

PCNSL histogenetic origin

Under normal circumstances, the CNS is an immunologically privileged site devoid of B-cells. Therefore, the cellular origin of PCNSL remains to be elucidated. One proposed mechanism suggests that a malignant B-cell clone arising systemically might express specific adhesion molecules that facilitate homing to the CNS. There, the tumor cells proliferate and undergo additional mutations in the absence of modulatory control by the host's immune system. It remains unknown whether PCNSL originates within the CNS or is part of a systemic lymphoma that escapes the immune system to multiply in the CNS ‘sanctuary’ [5]. B-cells recruited to the brain during an inflammatory response may remain for extended periods and eventually undergo malignant transformation while localized within the CNS. Alternatively, B-cells may transform into a malignant state outside the CNS, for example, during a GC response in a secondary lymphoid organ [5].

It is possible that both mechanisms play a role. However, the selective homing of a malignant B-cell solely to the brain cannot be easily explained and remains difficult to validate experimentally. To date, no specific cell adhesion molecule, chemokine or cytokine has been identified that predicts selective B-cell homing to the brain in PCNSL, nor have significant differences in adhesion molecule expression been found between PCNSL and systemic lymphomas [18].

The B-cell differentiation process may provide insights into the histogenetic origin of PCNSL. The primary phase involves the assembly of the V, D, and J sections of the immunoglobulin (Ig) heavy and light chain genes in the bone marrow [9]. Following successful assembly, naïve B-cells exit the bone marrow for the next phase of maturation, where they interact with antigens in the GCs of secondary lymphoid organs, to improve their B-cell receptor (BCR) binding affinity. The process of somatic hypermutation (SHM) in the first 1.5-2.0 kb of the V region genes is regulated within the GCs [10]. This process and affinity maturation require specific antigens, antigens-presenting cells (APC) and T-cells, and the presence of BCL6 [11]. SHM may either increase or decrease

BCR affinity, leading to the selection of B-cell clones for further rounds of SHM. Eventually, these cells either undergo apoptosis or exit the GCs [12]. After SHM, B-cells may undergo Ig class-switch recombination, substituting the BCR μ constant region with downstream regions to generate various antibody classes [5].

Sequence analysis of Ig variable region genes in PCNSL has detected high frequencies of somatic mutations. These findings indicate that PCNSLs originate from mature B-cells that have been exposed to antigens and have undergone T-cell-dependent affinity maturation within a GC microenvironment [66]. Morphologically, PCNSL cells resemble Centro blasts, and the presence of SHMs in rearranged Ig segments demonstrates their prior involvement in a GC reaction [13].

Expression of B cell markers such as CD19, CD20, and CD79a, is present in almost all PCNSLs. CD10 is present in 10-20% of cases, while plasma cell markers (CD38, CD 138) are generally absent. Further immunophenotype characterization has shown that these tumors possess overlapping features of GC and activated B-cell differentiation. Specifically, immunohistochemical analyses have demonstrated that the majority of brain lymphomas express MUM-1, an activated B-cells marker, and BCL-6, a GCs marker [40], as previously confirmed [8]. BCL-2 and BCL-6 are expressed in 56%-93% and 60%-80% of PCNSL cases, respectively [6]. BCL-6 serves as the dominant regulator of the GC reaction and suppresses the exit of B-cells from the GCs [23]. Strong IRF4/MUM1 expression is observed in approximately 90% of PCNSLs, indicating that the tumor cells are transitioning out of the GC. Since IRF4/MUM1 expression is more frequently associated with memory B-cells than with GC-B cells, the CD10-BCL6+IRF4/MUM1+ phenotype suggests that further B-cell maturation is impaired. This corresponds to a late GC exit phenotype and is associated with a poor prognosis [5].

Biological analyses have demonstrated that PCNSL is at the late B-cell GC exit phase and exhibits constitutive Nuclear Factor- κ B (NF- κ B) activity. This activity is driven by mutations in BCR pathway genes, the Toll-like receptor (TLR) pathway (notably MYD 88), and CARD11 [5, 9-13]. Recently, DLBCL has been categorized into distinct molecular clusters. PCNSL has been closely associated with the MCD subtype (defined by the co-occurrence of MYD88L265P and CD79B mutations) or the cluster 5 (C5) DLBCL. Both classifications converge on the presence of recurrent MYD88L265P, PIM1, CD 79B, and BTG2 mutations, as well as Ig heavy locus (IgH)-BCL6 translocations. Other hallmarks include copy number gains at 3q12.3 and 9p24. (involving PD-L1/PD-L2) and copy losses at 6p21-22 (human leukocyte antigen, HLA, locus), 6q21, and 9p21.3 (CDK N2A biallelic loss) [5,26]. Although recent reports have suggested a significant role for the tumor microenvironment in PCNSL pathogenesis, a comprehensive survey examining its interaction with mutation and methylation events is currently lacking [5,14-17].

PCNSL genomic alterations

During SHM phases, B-cell differentiation requires DNA double-strand breaks, consequently, the failure to accurately repair these breaks may lead to the emergence of malignant cells. PCNSL cells frequently harbor translocations affecting Ig and Ig-related genes, most notably BCL6 [23]. Constitutive BCL-6 activity, often caused by mutations in its promoter, can exert significant tumorigenic effects. The Cancer and Leukemia Group B (CALGB) 50202 trial demonstrated that BCL-6 overexpression is associated with poorer survival and refractory disease status [27]. Although these findings have been supported by other studies [67], various retrospective analyses have yielded conflicting results [5,8].

Next-Generation Sequencing (NGS) has revealed that over 80% of non-conservative mutations occur within loci encoding proteins such as TP53, ATM, PTEN, JAK3, PIK2 CA, PTPN11, CTNNB1, and KRAS [15]. Specifically, mutations in the TP53 and ATM genes may be critically involved in the PCNSL molecular pathophysiology. Furthermore, non-synonymous somatic mutations in MYD88, PIM1, and Btg2 have been

detected at high frequency via whole-exome sequencing in PCNSL samples [14]. Deletions and insertions of genetic material are highly frequent in PCNSL. Comparative genomic hybridization (CGH) has identified several critical genetic abnormalities. The most common genomic alteration involves the deletion of the chromosome 6p21 region, which harbors the HLA locus [17]. Deletions on chromosome 6q are also frequent, particularly at the 6q21-23 [16] locus. This region contains PTPRK, a protein tyrosine phosphatase implicated in cell adhesion signaling, PRDM1, a tumor suppressor and regulator of B-cell differentiation, and A20 (TNFAIP3), a negative regulator of the NF- κ B signaling pathway.

While 6q deletions are associated with adverse outcomes in follicular lymphoma [68], they are present in 66% of PCNSL specimens. Reduced expression of PTPRK, a candidate tumor suppressor, is associated with 6q22-23 deletion, suggesting its role in PCNSL progression. LOH analysis has also shown that 6q aberrations predict shorter survival. Recurrent chromosomal losses have also been recorded at the 9p21 locus [16], which contains CDKN2A and other genes involved in cell cycle regulation.

Chromosomal gains on chromosome 12 are very common, specifically at the 12q locus harboring CDK4, MDM2, STAT6, and GLI1 [16,18-20]. Distinct alterations also occur on the long arms of chromosomes 1, 7, and 18 [18], whereas DNA copy number losses are frequently found on chromosome 6 and the short arms of chromosomes 17 and 18. CNAs and translocations on chromosome 9p24, involving the PD-L1 and -2 genes, are frequent, suggesting that immune escape is critical to PCNSL pathophysiology [23]. Homozygous loss of HLA class II [24] and CDKN2A, along with TBL1XR1 variants, are common features that align PCNSL with the recently described [27] "MCD", "C5", or "MYD 88-like" subtypes, which are hypothesized to originate from long-lived memory B-cells [27,69-71].

Less research has been conducted on molecular pathogenesis of PCNSL compared with systemic. A molecular aberration in PCNSL that has been reproducibly detected is homozygous deletion or promoter hypermethylation of the CDKN2A gene, which is responsible for P14ARF production. Growth arrest mediated by P14ARF is p53-dependent as p14ARF binds to MDM2, a mediator of p53 stabilization. TP53 mutations are infrequent genomic events in PCNSL, in contrast to systemic lymphomas in which TP53 gene inactivation may be observed in 20% to 40% of tumors. These findings indicate that early alterations of CDKN2A in PCNSL contribute to tumor development and reduce the selective pressure for secondary TP53 mutations [19]. Deletion of CDKN2A, CDKN1B, and RB1 have also been reported in PCNSL cases [18,19].

The Janus kinase (JAK/STAT) signaling pathway plays a central role in the biology of PCNSL, according to molecular analyses. Transcript and protein levels of IL-4 and IL-10 which act as mediators of the JAK/ STAT intracellular signaling pathway and promote B cell proliferation, are upregulated in the tumor microenvironment, as well as in the vitreous and cerebrospinal fluid (CSF) [8]. These cytokines have been associated with tumor response and disease progression [8,28]. The upregulation of IL-4 and IL-10 and activation of downstream JAK/STAT signaling are linked to aberrant MYD88 activation, which is involved in TLR signaling [29]. Increased intratumoral levels of JAK1 transcripts have also been observed in PCNSL [23,28]. Approximately 55% of PCNSL cases harbor mutations within the Toll/IL-1 receptor (TIR) domain of MYD 88, most commonly the L265P mutation, which results from a leucine-to-proline at position 265 and contributes to lymphomagenesis, particularly in PCNSL and activated DLBCL [72].

A L265P substitution in MYD88 is observed in 38%-50% of PCNSL cases, and CD79B is mutated in approximately 20% of cases [17]. Other studies have reported MYD88 mutation frequencies ranging from 38% and 94% in PCNSL cases [27,73,74], which may reflect selection bias due

to small cohort sizes, given the rarity of the disease. MYD88 encodes a signaling adaptor protein that regulates NF- κ B activation and the JAK/STAT3 signaling pathway following stimulation of TLRs, Il-1/Il-18 receptors, and Interferon- β (IFN- β) production. The MYD88 L265P mutation and loss of CDKN2A have been identified as early mutational events in PCNSL [75]. Although TP53 alterations play a relatively minor role in PCNSL pathogenesis, the CDKN2A/B locus encodes multiple proteins that regulate key cell-cycle control pathways, including the p53 pathway (via p14 ARF) and the RB1 pathway (via p16 INK4a), underscoring the importance of p53-associated mechanisms in PCNSL biology [76].

The CD 79B gene encodes a subunit of the BCR complex that is essential for BCR signaling, and subsequent NF- κ B activation. Approximately 40% of PCNSL cases harbor mutations within the immunoreceptor tyrosine-based activation motif of CD79B, most commonly at tyrosine 196 (Y196), leading to chronic active BCR signaling and sustained NF- κ B pathway signaling activation [77]. In contrast, systemic DLBCL exhibits lower frequencies of MYD88 and CD79B in the active B-cell (ABC) subtype, with reported rates of 8%-37% for MYD88 and 12%-22% for CD79B mutations [29,78].

The BCR pathway transmits its signals to the CARD11-BCL10-MALT1 (CBM) signalosome complex. Less common mutations as well as overexpression of CARD11 [21] and MALT1 [22] have also been observed in PCNSL cases. Bruton tyrosine kinase (BTK) serves as a key mediator linking BCR and TLR signaling pathways to downstream NF- κ B activation. In more than 90% of PCNSL tissue samples, components of the BCR, TLR, or NF- κ B signaling pathways are altered. The BCR and TLR pathways, along with their downstream target NF- κ B, are frequently affected by SHM, particularly in genes encoding MYD88 and CD79B. NF- κ B signaling appears to be the dominant pathway involved in PCNSL pathogenesis [26,79,80], playing a critical role in transcriptional regulation and cell survival. Constitutive activation of NF- κ B promotes cellular proliferation, inhibits apoptosis, and sustains the viability of activated ABC DLBCL [80]. NF- κ B activity is further enhanced by mutations or deletions of tumor necrosis factor alpha induced protein 3 (TNFAIP3) [73]. The majority of PCNSLs are of the non-GCB-DLBCL subclass and share many genetic aberrations with non-CNS ABC-DLBCL within the same signaling pathways. SHM has been reported to contribute to PCNSL pathogenesis, with a higher mutational load than in systemic DLBCL [13]. SHM targets identified in PCNSL include proto-oncogenes such as PIM1, PAX5, BTG2, and OSBPL10 [13,26].

Despite extensive genetic studies of PCNSL [5,26,75,81], reports on global gene expression profiling remain limited. Available studies indicate that PCNSL exhibit distinct gene expression profiles, which differentiate them from systemic ABC-DLBCL. These differences are particularly evident in the expression of Ig constant genes, highlighting the role of B-cell maturation in the classification of PCNSL and other lymphomas, similar to approaches used in leukemia and multiple myeloma [82].

MYC, a transcription factor commonly upregulated in DLBCL via translocation, drives cell proliferation and regulates cell development, differentiation, and apoptosis, partly through downregulation of BCL2 [83,84]. In PCNSL, microRNAs associated with the MYC signaling pathway have been reported, with tumor-suppressor microRNAs such as miR-193b, miR-199a, miR-145, and miR-214 being downregulated [30].

Epigenetic alterations in PCNSL

Epigenetic silencing through DNA methylation is also involved in the pathogenesis of PCNSL. DNA hypermethylation has been found in various loci such as CDKN2A, p16 INK4a, DAPK, p14ARF, MGMT, and RFC [32,33]. Array-based DNA methylation profiling identified 194 distinctively methylated genes when comparing PCNSL patients to controls. A significantly enriched CpG content was also observed in these

differentially methylated genes. However, no differences in methylation patterns between PCNSL and systemic DLBCL cases were recorded [85]. Additionally, promoter methylation of RB1 and CDKN1B has been found in PCNSL cases [18,20].

PCNSL are highly proliferative neoplasms [86]. TERT activation leads to unlimited proliferation, and activating TERT promoter mutations are frequent in various human cancers [34]. Mutations at two hotspot positions (-124G>A and -146G>A) result in enhanced TERT promoter activity. Bruno et al. have found that these TERT promoter mutations were present in PCNSL located in the splenium [35].

MicroRNAs may also play a critical role in the PCNSL pathogenesis as they do in other malignant neoplasms. MiR-17-5p, which targets the proapoptotic gene E2F1, was significantly upregulated in nine PCNSL cases compared with nodal DLBCL cases [87]. It has also been reported that miRNA upregulation is associated with overexpression induced by inflammatory cytokines (miR-155), inhibition of terminal B cell differentiation (miR-30b/c, miR-9), or the MYC pathway (miR-92, miR-17-5p, miR-20a) [30].

Nevertheless, Deckert et al. [5] reported contradictory outcomes. Specifically, they observed that miR-155 exhibited the lowest expression level compared with other mi-RNAs implicated in PCNSL. CSF analysis from PCNSL patients demonstrated that miR-19, miR-21, and miR-92 were expressed at significantly higher levels than in controls with inflammatory CNS diseases, highlighting the potential of these miRNAs as clinical bio-markers [31].

The role of tumor microenvironment in PCNS pathogenesis

Under normal conditions, the brain is immunologically “quiet”, whereas some PCNSL specimens exhibit signs of inflammatory reactions, including activated macrophages and reactive T-cell infiltration. In the CNS perivascular area, T cells residing near blood vessels may interact with perivascular antigen-presenting macrophages. Subsequent invasion of the CNS parenchyma requires antigen stimulation. In the absence of antigen, T cells may remain confined to the perivascular region [88]. Activated perivascular infiltration by CD8 T cells may be associated with favorable outcomes, suggesting the potential efficacy of immunotherapy in enhancing T-cell-mediated immune-surveillance [89].

Inflammatory activation may precede or accompany PCNSL [90]. Chemokines regulate leukocyte trafficking, proliferation and adhesion, contributing to the organization of normal lymphoid structures. A recent study reported high expression of the B-cell-attracting chemokine BCA-1 (CXCL-13) in PCNSL. This chemokine promotes B-cell homing to secondary lymphoid organs. BCA-1 binds to its receptor, CXCR5, which is also expressed by B-cells in PCNSL, and may facilitate the extranodal localization of CNS lymphomas. Although BCA-1 is expressed by lymphoma cells, it is not produced by tumor endothelia in PCNSL and therefore, does not contribute to the angiogenic growth pattern of these tumors [36].

Mechanisms underlying the intracerebral tropism and dissemination of lymphoma cells are central to PCNSL pathogenesis and may involve chemokines such as CXCL-13, and CXCL12 (SDF-1). The diagnostic relevance of Il-10 and CXCL-13 concentration in CNS lymphomas has been demonstrated [37,38]. Elevated CFS levels of CXCL-13 and Il-10 are also associated with poor prognosis in PCNSL patients [36,91].

Furthermore, ectopic expression of the B-cell growth factor Il-4 was also detected in PCNSL [8]. Il-4 may function as an autocrine growth factor for lymphoma cells and as a paracrine factor due to its unique expression by tumor-associated endothelia in PCNSL. Il-4 is not expressed in the normal brain vasculature or in malignant astrocytic neoplasms. These findings support the hypothesis that Il-4 play a critical role in PCNSL pathogenesis and progression and may contribute to the angiogenic growth pattern of lymphoma cells within the CNS. Additionally, the activated form of the transcription factor STAT6, a mediator of Il-4-

dependent gene expression, is expressed by tumor cells and tumor-associated endothelia in PCNSL, providing further evidence for the functional significance of Il-4 signaling in PCNSL [92].

Hemangioblastoma

Epidemiological data

Hemangioblastoma (HB) is a highly vascular tumor, accounting for 3% of all CNS tumors, 1-2.5% of primary intracranial tumors [39], 7-8% of posterior cranial fossa tumors [40], and 7-10% of spinal cord tumors. It is generally benign, characterized by neoplastic “stromal” cells embedded with in a dense network of vascular channels [41]. Cystic HBs are more commonly located in the cerebellar hemispheres and, more broadly, in a limited subset of CNS regions, including retina, brainstem, and spinal cord [39-41].

HBs may arise sporadically or as part of von Hippel-Lindau (VHL) disease, an autosomal dominant disorder, which accounts for approximately 25% of cases [40]. About 75% of HBs are sporadic, and somatic VHL mutations have been detected in only a small subset of these tumors [42]. In contrast to familial VHL disease, most sporadic HBs do not exhibit detectable germline or somatic alterations in VHL [43,44]. Sporadic cases typically present as solitary lesions, whereas VHL patients often develop multiple HBs [45]. Two possible explanations have been proposed for the difference in VHL mutation frequency between familial and sporadic HBs. The first suggests that sporadic HBs may arise from alterations in hypoxia-sensing pathway other than VHL, producing a histologically-identical phenotype with excessive angiogenesis. A candidate gene is TCEB1, which encodes.

VHL-binding partner belonging C. Genomic sequencing of clear cell renal carcinoma has shown somatic mutations in TCEB1 in a minority of cases lacking VHL mutations. The second explanation is that earlier bulk sequencing techniques were technically limited and may have underestimated the full extent of VHL inactivation [93]. Despite their classification as benign WHO grade 1 tumor [94], HBs are associated with significant morbidity due to the cumulative effects of the primary tumor or development of peritumoral cysts, which are often large [95]. In some cases, tumor recurrence or progression may occur [96] and, more rarely, leptomeningeal dissemination has been reported [97].

HB cell of origin

It remains unclear whether HBs originate from an embryologically arrested “hem angioblast” stem cell that has subsequently differentiates into the distinct cellular component supporting the tumor architecture [41,46]. A series of immunohistochemical and ultrastructural studies have failed to clarify the origin of the stromal cells. Consequently, HBs remain classified as tumors of “uncertain histogenesis” [47]. Decades ago, it was hypothesized that HBs arise from a “congenital anlage”, with histologic features reflecting an “embryologic type of the tumor cell [48]. Stein et al. [98] suggested an Angio mesenchymal origin for HB, based on developmental biology observations originally described by Sabin [99]. Sabin [99] and Murray [100] investigated the morphologic evolution of embryonic Angio mesenchymal tissue into hem angioblasts. However, the hem angioblast itself remained an “hypothetical” cell until Choi et al. [101] reported the identification of a common precursor for hematopoietic and endothelial cells. The generation of hem angioblasts from embryonic stem cells [101] enabled detailed analysis of gene and protein expression during embryonic hematopoiesis and vasculogenesis.

Consequently, several proteins have been identified that are directly associated with pre-mesangioblast and hemangioblastic differentiation [102]. These include growth factors, transcription factors and transmembrane receptors such as brachyury, Scl, Csf-1R, Gata-1, Flk-1, and Tie-2 [103]. Various hypotheses regarding HB histogenesis have been proposed implicated glial, endothelial, arachnoid, neuroendocrine, fibro-histiocytic cells, embryonic choroid plexus, neuroectodermal cells,

or heterogeneous cell populations [104]. These unresolved interpretations have led to the current WHO classification of HBs as neoplasms of “uncertain histogenesis” [47]. Although earlier immunohistochemical studies were unable to definitively identify the origin of stromal cells, the complex immunophenotype combined with their unique morphology may suggest that these cells lack a direct cytologic counterpart in mature brain tissue or in tissues outside the CNS.

Other investigators, based on the morphologic heterogeneity of HBs, have focused on the cytogenetic relationship between stromal and vascular cells. Some studies [105,106] have suggested differentiation of stromal cells into vascular cells, whereas others detected no transition of stromal cells into ‘Vaso formative’ elements and suggested that vascular and stromal cells represent distinct cytologic components [107,108]. However, another report identified ultrastructural evidence of Weibel-Palade body formation within the cytoplasm of stromal cells, suggesting vascular differentiation potential of these cells [109].

Proteins expressed during early hem angioblast differentiation have recently identified, including Scl, also known as Tal-1, which regulates proliferation and self-renewal of multipotent hematopoietic cells [110] and acts as a regulator of erythroid cells differentiation [111], as well as brachyury, a transcription factor essential for posterior mesoderm formation, differentiation, and axial development in vertebrates [103]. Additional proteins involved to vasculogenesis, Flk-1 and Tie-2, and hematopoiesis, Csf-1R and Gata-1, have also been associated with hemangioblast development [103]. Flk-1, also known as kdr, is a receptor tyrosine kinase whose ligand is Vascular Endothelial Growth Factor (VEGF), a key mediator of endothelial cell differentiation. The Tie-2 receptor tyrosine kinase plays an important role in angiogenesis, particularly in vascular network formation. Csf-1R is a transmembrane protein tyrosine kinase receptor for Csf-1, a macrophage-specific growth factor. Gata-1 is a tissue-specific transcription factor essential for erythroid and megakaryocytic development [112]. Notably, these proteins were consistently expressed in HB stromal cells, an observation that strongly supports the hypothesis that embryonic progenitor cells with hemangioblastic differentiation potential represent the cytologic counterpart of the stromal cell population.

Another model suggests that stromal cells are genetically distinct due to VHL deficiency and promote reactive angiogenesis by recruiting normal endothelial cells through pseudo-hypoxia-mediated paracrine signaling. This model contrasts with the alternative hypothesis of an embryologically arrested, heritable “hemangioblast” clone that transdifferentiates into the diverse cellular components comprising the tumor [46,113]. Accordingly, it has been suggested that HBs are primarily comprised of developmentally arrested hemangioblastic stem cells with the capacity to differentiate into primitive vascular structures and RBCs, analogous to embryonic angioblastic mesenchyme [39].

In areas of blood island differentiation within HBs, co-expression of Erythropoietin (Epo) and its receptor (Epo-R) has been demonstrated [114]. Epo-R is expressed during early embryonic blood island formation in mice between embryonic days 8.0 to 9.5 [115] and is upregulated during early blood island differentiation [115]. Epo is a HIF target protein and is upregulated following HIF activation in VHL-deficient stromal cells. Consequently, it has been suggested that the concurrent expression of developmental proteins and HIF target proteins may establish autocrine and paracrine signaling loops that promote tumor growth. Following the observation of consistent Tie-2 expression in stromal cells, co-expression of Ang-1, another HIF target protein was investigated [116].

These findings led to the identification of a potential Tie-2/Ang-1 autocrine/paracrine loop in HB stromal cells. This discovery was preceded by the demonstration of three additional potential autocrine/paracrine loops, transforming growth factor- α (TGF- α), another HIF target protein [117], and its receptor [118], Flk-1 and its HIF-regulated ligand VEGF [119], and stromal cell-derived factor-1 (SDF-1)

with its receptor CXCR4 [120]. Moreover, the Tie-2/Ang-1 autocrine/paracrine loop has also been identified in other human neoplasms [121].

Molecular Biology of HB

Despite the presence of CNAs in a small subset of cases [53], the HB exome is notably simple and lacks additional oncogenic driver mutations [52,54]. These tumors are largely diploid with few chromosomal abnormalities [49,50], and have served as prototypic lesions for studying genomic drivers of hypoxia-mediated metabolism in cancer [42]. VHL mutations are detected in approximately 10% to 44% of sporadic HBs [51]. The reported frequency of chromosome 3 aneuploidy in sporadic tumors ranges from 18% to 69% [49,50]. However, only one report identified concurrent somatic VHL mutation and LOH of VHL in one of 13 sporadic HBs [50], while another detected missense mutation with VHL deletion by comparative genomic hybridization in two of 16 sporadic HB cases [49]. These findings may be explained by low VHL mutant allele fractions restricted to the neoplastic “stromal” cell population in sporadic HBs, in contrast to familial tumors, which are characterized by heterozygous germline VHL mutations.

Mutations of the VHL tumor suppressor gene, located on chromosome 3p 25.3 appear to play a role in both sporadic and VHL disease-associated tumors [52-54]. However, the genetic determinants underlying the clinical heterogeneity of HBs remain largely unknown. Loss of chromosome 3p or the entire chromosome 3 represents the most common cytogenetic abnormality in HBs. Other recurrent abnormalities include losses of chromosome regions 1p11-p31, chromosome 9,12 (q24.13), and 18q, as well as gains of chromosome regions 1 (p36.32), 7 (p11.2), and chromosome 19 [122].

Transcriptomic and lipidomic analyses of cystic and solid HBs have identified dysregulation of lipid metabolism-related genes in cyst-forming tumors [123], however the under-lying molecular mechanisms remain unclear. In a recent study by Takayanagi et al., molecular characterization of the VHL promoter revealed epigenetic differences between sporadic and VHL-associated HBs [53], raising the possibility that DNA methylation alterations may define biologically relevant subgroups.

Mutations in ARID1B, a tumor suppressor gene implicated multiple cancer types [55,56], have also been reported. Further studies are required to determine whether these sub clonal variants are functionally significant in driving sporadic HB development [57]. HBs are composed of vascular and “stromal” cells. The neoplastic “stromal” cells account for

approximately 10-20% of the total tumor cell population, while the remainder consists of vascular endothelial cells, pericytes, and other nucleated cells, such as lymphocytes, present within the vascular channels [104]. LOH analyses of micro dissected stromal cells have demonstrated that these cells represent the neoplastic, VHL-deficient component of HBs [104,114,124].

As previously discussed, the high prevalence of recurrent somatic VHL mutations (approximately 50%) and LOH at the chromosome 3p (approximately 72%) leads to biallelic VHL inactivation in 47% of sporadic HBs and inactivation of at least one VHL allele in 78% of cases [52]. Biallelic VHL loss results in impaired degradation of HIF-1 α , which subsequently drives aberrant transcription of hypoxia-responsive genes, including VEGF and PDGFB [125]. Consequently, the tumor mass is composed predominantly of non-neoplastic endothelial cells and surrounding pericytes, with only a minor fraction consisting of neoplastic “stromal” cells that harbor the driver genetic alterations. Thus, HB tumorigenesis appears to be consisted of a small subpopulation of neoplastic stromal cells that recruit and interact with various non-neoplastic cellular components to generate the characteristic tumor architecture [39,126].

The Notch signaling pathway appears to be involved in HB pathogenesis [127]. Additional candidate genes implicated in HB development include EGFR, PTCH, RB1, PTPN11, FLT3, IRF4, FGFR1, CHEK2, PRDM16, MKL1, GPHN, FOXP1, GPC3, IKZF1, HOXA9, HOXA11, HOXC13, HOXC11, HOXD11, and HOXD13 [122]. Copy number gains involving miR-551a (located within the PRDM16 locus), as well as gains of miR-196a-2 and miR-196b, have also been identified in HB samples [122].

Conclusion

PCNSL and HB consist Ute a complex group of diseases characterized by marked genomic, biological and clinical heterogeneity. Neoplastic subtypes harboring alterations in genes that play critical roles in CNS development have been identified, and murine models based on several of these findings have been established. Significant progress has been made in elucidating the molecular pathogenesis of PCNSL leading to the clinical use of targeted therapeutic agents, including those aimed at inhibiting NF-kB pathway activation. However, further investigation is required to clarify the spectrum and functional significance of molecular alterations responsible for uncontrolled cell proliferation in the majority of these neoplasms.

Hemangioblastoma	Molecular alterations
Tumor suppressor genes inactivation	VHL (located on chromosome 3p25-26) [52-57]
Functional VHL protein (pVHL) loss	Overproduction of VEGF [112, 119], PDGFB [124,125], Epo [114,115]
Copy Number Variations (CNVs)	Chromosome 12q (including PTPN11 gene), 1p11-p31, 3p13 (FOXP1), 6q, 8p11.22 (FGFR1), 12q24.13,13q12.2 (FLT3),18q,22q13.1 (MKL1), 22q12.1 (CHEK2) loss [122], Chromosome 1p36.32 and 7p11.2 gains (including EGFR gene) [59], chromosome 19, 2q31.1 (HOXD11, HOXD13, HOXD1, 1HOXD13) 9q22.32 (PTCH),12q13.13 (HOXC 13, HOXC11), Xq26.2 (GPC3) gain [122]
Loss of Heterozygosity (LOH)	Chromosome 6q (sometimes concurrent with 3p loss, possible involvement of ZAC1 tumor suppressor gene) [107,114,123]
Gene mutations	ARID1B gene [55-57]
Signaling pathways alterations	EGFR overexpression [122], Notch receptor/ effector expression (especially NOTCH1, NOTCH4, HES1, HESS5) [127]
Candidate genes genomic aberrations	PRDM16, PTPN11, HOXD11, HOXD13, FLT3, FGFR1, FOXP1, GPC3, HOXC13, HOXC11, MKL1, IRF4, GPHN, IKZF1, RB1, HOXA9, HOXA11 and several microRNA, including hsa-miR-196a-2, and miR-551a [122]

Table 1: Molecular alterations in Hemangioblastoma

Primary Central Nervous System Lymphoma	Molecular alterations
Point mutation (non-Somatic Hypermutation (SHM)/a (aberrant) SHM)	Genes coding for ATM, TP53, PTEN, PIK3CA, JAK3, CTNNB1, PTPN11, KRAS [5,15], PIM1, BTG2 [5,13, 14, 26], MYD88 [5,10-14], CD79B [29,77,78], MALT1 [22], CARD11 [5,9-13,21], OSBPL10 [13,26]
SHM/aSHM	BCL6 promoter substitution [6-8], PIM1, PAX5 [35, 36,39,79], RhoH/TTF, MYC proto-oncogene activation [90,91], IGH (Immunoglobulin Heavy) locus translocation [90,99]
Genetic material gain	12q (STAT6, MDM2, CDK4, MDM2, GLI1) [16-20], 1q, 7q, 18q [18] leading to NF-kB activation
Genetic material loss	6p21 (HLA) immune escape [16,17], 9p21 (CDKN2A) proliferation [5,16,25,26], 6q21-23 [5,16,17,26] (PRDM1 tumor activation, A20 (TNFAIP3 NF-kB activation) [75,82]
DNA hypermethylation	CDKN2A [19,25,32,33,84-86], DAPK, p14 ^{ARF} , p16 ^{INK4A} , RFC, MGMT no expression [32,33], CDKN1B, RB1 [18- 20], TERT promoter mutations [34,35]
Deletion	CDKN2A [18,19,25,32,33,84,85], RB1, CDKN1B [18-20]

Table 2: Molecular alterations in Primary Central Nervous System Lymphoma

Accessibility's

Conflict of interest and source of funding statement: The Authors declare that they have no conflict of interests The study was self-funded by the author and co-Authors.

References

- Deckert M, Batchelor T, Ferry JA, et al. (2021). Primary diffuse large B-cell lymphoma of the CNS. In WHO Classification of Tumours, Central Nervous System Tumours, the WHO Classification of Tumors Editorial Board, 5th ed. IRAC: Lyon, France; Chapter 10: pp. 351-355.
- Hernandez-Verdin I, Kirasic E, Wienand K, et al. (2023). Molecular and clinical diversity in primary central nervous system lymphoma. *Ann Oncol*; 34:186-199.
- Abla O, Weitzman S. (2006). Primary central nervous system lymphoma in children. *Neurosurg Focus*; 21: E8.
- Louis DN, Perry A, Reifenberger G, et al. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol*; 131(6): 803-820.
- Deckert M, Montesinos-Rongen M, Brunn A, et al. (2014). Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. *Acta Neuropathol*; 127(2):175-188.
- Montesinos-Rongen M, Brunn A, Bentink S, et al., (2008). Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. *Leukemia*; 22(2):400-405.
- Lin CH, Kuo KT, Chuang SS, et al. (2006). Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphomas of central nervous system origin and peripheral nodal origin. *Clin Cancer Res*; 12:1152-1156.
- Rubenstein JL, Fridlyand J, Shen A, et al. (2006). Expression and angiogenesis in primary CNS lymphoma. *Blood*; 107(9):3716-3723.
- Jung D, Giallourakis C, Mostoslavsky R, et al., (2006). Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. *Annu Rev Immunol*; 24:541-570.
- Odegard VH, Schatz DG. (2006). Targeting of somatic hypermutation. *Nat Rev Immunol*; 6(8):573-583.
- Kurosaki T, Shinohara H, Baba Y. (2010). B cell signaling and fate decision. *Annu Rev Immunol*; 28:21-55.
- McHeyzer-Williams MG, McLean MJ, Nossal GJ, et al. (1992). The dynamics of T cell-dependent B cell responses in vivo. *Immunol Cell Biol* ;70 (Pt 2):119-127.
- Montesinos-Rongen M, Van Roost D, Schaller C, et al. (2004). Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. *Blood*; 103(5):1869-1875.
- Todorovic Balint M, Jelacic J, Mihaljevic B, et al. (2016). Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. *Int J Mol Sci*; 17(5): 683.
- Hattori K, Sakata-Yanagimoto M, Okoshi Y, et al. (2017). MYD88 (L265P) mutation is associated with an unfavorable outcome of primary central nervous system lymphoma. *Br J Haematol*; 177(3):492-494.
- Kreher S, Jöhrens K, Strehlow F, et al. (2015). impact of B-cell lymphoma 6 in primary CNS lymphoma. *Neuro Oncol*; 17(7): 1016-1021.
- Fukumura K, Kawazu M, Kojima S, et al. (2016). Genomic characterization of primary central nervous system lymphoma. *Acta Neuropathol*; 131(6):865-875.
- Rubenstein JL, Treseler P, O'Brien JM. (2005). Pathology and genetics of primary central nervous system and intraocular lymphoma. *Hematol Oncol Clin North Am*;19 (4):705-17, vii.
- Tilly H, Rossi A, Stamatoullas A, et al., (1994). Prognostic value of chromosomal abnormalities in follicular lymphoma. *Blood*; 84: 1043-1049.
- Nakamura M, Shimada K, Ishida E, et al. (2004). Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. *Histol Histopathol*; 19: 211-219.
- Pasqualucci L, Trifonov V, Fabbri G, et al., (2011). Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet*; 43(9): 830-837.
- Morin RD, Mungall K, Pleasance E, et al. (2013). Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing. *Blood*; 122(7): 1256-1265.
- Basso K, Dalla-Favera R. (2012). Roles of BCL6 in normal and transformed germinal center B cells. *Immunol Rev*; 247(1):172-183.
- Jordanova ES, Riemersma SA, Philippo K, et al. (2002). Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. *Gen Chrom Canc*; 35: 38-48.
- Riemersma SA, Jordanova ES, Schop RF, et al. (2000). Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. *Blood*; 96: 3569-3577.
- Schwint H, Akasaka T, Zühlke-Jenisch R, et al. (2006). Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic

- hypermutation or defective class switch recombination. *J Neuropathol Exp Neurol*; 65: 776-782.
27. Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. (2012). Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. *Clin Cancer Res*; 1;18(19):5203-5211.
 28. Hubschmann D, Kleinheinz K, Wagener R, et al. (2021). Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. *Leukemia*; 35: 2002-2016.
 29. Lacy SE, Barrans SL, Beer PA, et al. (2020). Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report. *Blood*; 135:1759-1771.
 30. Fischer L, Hummel M, Korfel A, et al. (2011). RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. *Neuro Oncol*;13(10):1090-1098.
 31. Baraniskin A, Kuhnhen J, Schlegel U, et al. (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. *Blood*; 117(11): 3140-3146.
 32. Chu LC, Eberhart CG, Grossman SA, et al. (2006). Epigenetic silencing of multiple genes in primary CNS lymphoma. *Int J Cancer*; 119: 2487-2491.
 33. Mrugala MM, Rubenstein JL, Ponzoni M, et al. (2009). Insights into the biology of primary central nervous system lymphoma. *Curr Oncol Rep*; 11: 73-80.
 34. Vinagre J, Almeida A, Pópulo H, et al. (2013). Frequency of TERT promoter mutations in human cancers. *Nat Commun*; 4:2185.
 35. Bruno A, Alentorn A, Daniau M, et al. (2015). TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium. *Acta Neuropathol*; 130: 439-440.
 36. Smith JR, Brazier RM, Paoletti S, et al. (2003). Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. *Blood*; 101(3): 815-821.
 37. Rubenstein JL, Wong VS, Kadoch C, et al. (2013). CXCL13 plus interleukin-10 is highly specific for the diagnosis of CNS lymphoma. *Blood*; 121(23):4740-4748.
 38. Sasayama T, Nakamizo S, Nishihara M, et al. (2012). Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immuno-competent primary central nervous system lymphoma (PCNSL). *Neuro Oncol*; 14(3): 368-380.
 39. Smith MJ, Wallace AJ, Bennett C, et al. (2014). Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. *J Pathol*; 234: 436-440.
 40. Deng MY, Sturm D, Pfaff E, et al. (2021). Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. *Nat Commun*; 12:5530.
 41. Park DM, Zhuang Z, Chen L, et al. (2007). von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. *PLoS Med*;4(2): e60.
 42. Louis DN, Perry A, Wesseling P, et al. (2021). The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol*; 23:1231-1251.
 43. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. (2021). EANO guideline on the diagnosis and management of meningiomas. *Neuro Oncol*; 23: 1821-1834.
 44. Ghaleb Amr M, Vincent W Yang. (2017). Krüppel-like factor 4 (KLF4): What we currently know. *Gene*; 611:27-37.
 45. Sievers P, Sill M, Blume C, et al. (2021). Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. *Acta Neuro pathol*; 2021; 141:281-290.
 46. Zhuang Z, Frerich JM, Huntoon K, et al. (2014). Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors. *Scientific Reports*; 4: 4102.
 47. Bohling T, Plate KH, Haltia M, et al. (2000). Von Hippel-Lindau disease and capillary hemangioblastoma. In: Kleihues P, Cawenee WK, editors. Pathology and genetics of tumors of the central nervous system. Lyon: WHO; p. 223-226.
 48. Lindau A. (1931). Discussion on vascular tumors of the brain and spinal cord. *Proc R Soc Med*; 24: 363-370.
 49. Guyot A, Duchesne M, Robert S, et al. (2019). Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma. *J Neurooncol*; 145:449-459.
 50. Sievers P, Hielscher T, Schrimpf D, et al. (2020). CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathol*; 140:409-413.
 51. Kim WY, Kaelin WG. (2004). Role of VHL gene mutation in human cancer. *J Clin Oncol*; 22(24):4991-5004.
 52. Wei D, Gong W, Kanai M, et al. (2005). Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. *Cancer Res*; 65(7):2746-2754.
 53. Takayanagi S, Mukasa A, Tanaka S, et al. (2017). Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system. *Neuro Oncol*; 19(9):1228-1236.
 54. Guo X, Gao L, Hong X, et al. (2019). Whole exome sequencing and immunohistochemistry findings in von Hippel-Lindau disease. *Mol Genet Genomic Med*; 7(9): e880.
 55. Zhao W, Hisamuddin I, Nandan M, et al. (2004). Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. *Oncogene*; 23: 395-402.
 56. Dwyer DC, Tu RK. (2017). Genetics of Von Hippel-Lindau Disease. *AJNR Am J Neuroradiol*; 38(3):469-470.
 57. Shibo Dong, Hongshan Chu, Ruisheng Duan, et al. (2025). Diagnosis and treatment of Von Hippel Lindau syndrome: A case series. *Experim Ther Med*; 30: 4.
 58. DM Kluin PM, Ferry JA. (2008) Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC Press; p. 240-241.
 59. Villano JL, Koshy M, Shaikh H, et al. (2011). Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. *Br J Cancer*; 105(9): 1414-1418.
 60. Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, et al. (2008). Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. *J Neuropathol Exp Neurol*; 67:1103-1111.
 61. Erdag N, Borade RM, Alberico RA, et al. (2001). Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. *AJR Am J Roentgenol*; 176(5): 1319-1326.
 62. Christian G, DeAngelis LM. (2017). Primary CNS Lymphoma. *J Clin Oncol*; 20; 35 (21): 2410-2418.
 63. Louis DN, Perry A, Reifenberger G, et al. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol*; 131:803-820.
 64. Hans CP, Weisenburger DD, Greiner TC, et al. (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*; 103(1): 275-282.
 65. Camilleri-Broet S, Martin A, Moreau A, et al. (1998). Primary central nervous system lymphomas in 72 immunocompetent

- patients: pathologic findings and clinical correlations. Groupe Ouest Est d' etude des Leucemies et Autres Maladies du Sang (GOELAMS). *Am J Clin Pathol*; 110(5): 607-612.
66. Montesinos-Rongen M, Kuppers R, Schluter D, et al. (1999). Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. *Am J Pathol*; 155: 2077-2086.
 67. Rubenstein JL, Hsi ED, Johnson JL, et al. (2013). Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). *J Clin Oncol*; 1; 31(25): 3061-3068.
 68. Oren L, Deangelis LM, Filippa DA, et al. (2008). Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. *Cancer*; 112(1): 151-156.
 69. Chapuy B, Stewart C, Dunford AJ, et al. (2018). Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med*; 24: 679-690.
 70. Venturutti L, Melnick A. (2020). The dangers of deja vu: Memory B-cells as the cell-of-origin of ABC-DLBCLs. *Blood*; 2020005857.
 71. Venturutti L Teater M, Zhai A, Chadburn A, et al. (2020). TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate. *Cell*; 182: 297-316.e227.
 72. Roy S, Josephson A, Fridlyand J, et al. (2008). Protein biomarker identification in the CSF of patients with CNS lymphoma. *J Clin Oncol*; 26(1):96-105.
 73. Aurélie B, Boisselier B, Labreche K, et al. (2014). Mutational analysis of primary central nervous system lymphoma. *Oncotarget*; 5(13): 5065-5075.
 74. Yamada S, Ishida Y, Matsuno A, et al. (2015). Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. *Leuk Lymphoma*; 56: 2141-2145.
 75. Nayyar N, White MD, Gill CM, et al. (2019). MYD88 L265P mutation and CDKN 2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. *Blood Adv*; 3: 375-383.
 76. Tao W, Levine AJ. (1999). p19 (ARF). stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. *Proc Natl Acad Sci USA*; 96: 6937-694.
 77. Nakamura T, Tateishi K, Niwa T, et al. (2016). Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. *Neuropathol Appl Neurobiol*; 42(3):279-290.
 78. Vlahopoulos SA. (2017). Aberrant control of NF-kappa-B in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode. *Cancer Biol Med*; 14(3): 254-270.
 79. Ngo V, Young R, Schmitz R, et al. (2011). Oncogenically active MYD 88 mutations in human lymphoma. *Nature*; 470: 115-119.
 80. Knittel G, Liedgens P, Korovkina D, et al. (2016). B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. *Blood*; 127(22): 2732-2741.
 81. Zhou Y, Liu W, Xu Z, et al. (2018). Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes. *Neoplasia*; 20: 1059-1069.
 82. Bødker JS, Brøndum RF, Schmitz A, et al. (2018). A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. *Blood Adv*; 2: 2400-2411.
 83. Nosrati A, Monabati A, Sadeghpour A, et al. (2019). MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type. *Ann Hematol*; 98(1):169-173.
 84. Kalkat M, De Melo J, Hickman KA, et al. (2017). MYC Deregulation in Primary Human Cancers. *Genes* (Basel); 8(6).
 85. Julia R, Ammerpohl O, Martín-Subero JI, et al. (2009). Array-based DNA methylation profiling of primary lymphomas of the central nervous system. *BMC Cancer*; 9: 455.
 86. Sugita Y, Muta H, Ohshima K, et al. (2016). Primary central nervous system lymphomas and related diseases: Pathological characteristics and discussion of the differential diagnosis. *Neuropathol*; 36:313-324.
 87. Robertus JL, Harms G, Blokzijl T, et al. (2009). Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. *Mod Pathol*; 22: 547-555.
 88. Marija P, Bartholomäus I, Kyratsous NI, et al. (2013). 2-photon imaging of phagocyte-mediated T cell activation in the CNS. *J Clin Invest*; 123(3):1192-201.
 89. Ponzoni M, Berger F, Chassagne-Clement C, et al. (2007). Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. *Br J Haematol*; 138(3):316-323.
 90. Lu JQ, O'Kelly C, Girgis S, et al. (2016). Neuroinflammation preceding and accompanying primary central nervous system lymphoma: case study and literature review. *World Neurosurg*; 88:692. e1-692.e8.
 91. Lars F, Korfel A, Pfeiffer S, et al. (2009). CXCL13 and CXCL12 in central nervous system lymphoma patients. *Clin Cancer Res*; 15(19): 5968-5973.
 92. Young KH, Fang Yu, Cai Q. (2019). Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment. *Translation Oncol*; 12(3): 523-538.
 93. Sato Y, Yoshizato T, Shiraiishi Y, et al. (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat Genet*; 45(8):860-867.
 94. Louis DN, Perry A, Wesseling P, et al. (2021). The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol*; 23(8): 1231-1251.
 95. Wang Q, Cheng J, Zhang S, et al. (2020). Central nervous system hemangioblastomas in the elderly (over 65 years): clinical characteristics and outcome analysis. *Clin Neurol Neurosurg*; 189:105622.
 96. Liao C-C, Huang Y-H. (2014). Clinical features and surgical outcomes of sporadic cerebellar hemangioblastomas. *Clin Neurol Neurosurg*; 125:160-165.
 97. Oya S, Takayanagi S, Takami H, et al. (2021). Masked malignant phenotype with a benign appearance: beat-up copy number profile may be the key for hemangioblastoma dissemination. *Brain Tumor Pathol*; 38(1):71-77.
 98. Stein AA, Schilp AO, Whitfield RD. (1960). The histogenesis of hemangioblastoma of the brain. *J Neurosurg*; 17:751.
 99. Sabin FR (2002). Preliminary note on the differentiation of angioblasts and the method by which they produce blood-vessels, blood-plasma and red blood-cells as seen in the living chick. 1917. *J Hematother Stem Cell Res*; 11(1):5-7.
 100. Murray PDF (1932). The development in vitro of the blood of the early chick embryo. *Proc R Soc London*; 111: 497-521.
 101. Choi K, Kennedy M, Kazarov A, et al. (1998). A common precursor for hematopoietic and endothelial cells. *Development*; 125:725-732.
 102. Gering M, Rodaway AR, Gottgens B, et al. (1998). The SCL gene specifies haemangioblast development from early mesoderm. *EMBO J*; 17:4029-4045.
 103. Huber TL, Kouskoff V, Fehling HJ, et al. (2004). Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. *Nature*; 432:625-630.
 104. Ohnishi S, Ohnami S, Laub F, et al. (2003). Downregulation and growth inhibitory effect of epithelial-type Krüppel-like

- transcription factor KLF4, but not KLF5, in bladder cancer. *Biochem Biophys Res Commun*; 308(2): 251-256.
105. Jurco S III, Nadji M, Harvey DG, et al. (1982). Hemangioblastomas: histogenesis of the stromal cell studied by immunocytochemistry. *Hum Pathol*; 13:13-18.
 106. Ho K. (1984). Ultrastructure of cerebellar capillary hemangioblastoma. I. Weibel-Palade bodies and stroma cell histogenesis. *J Neuropathol Exp Neurol*; 43: 592-608.
 107. Becker I, Paulus W, Roggendorf W. (1989). Histogenesis of stromal cells in cerebellar hemangioblastomas. *Am J Pathol*; 134:271-275.
 108. Nemes Z. (1992). Fibrohistiocytic differentiation in capillary hemangioblastoma. *Hum Pathol*; 23:805-810.
 109. Lach B, Gregor A, Rippstein P, et al. (1999). Angiogenic histogenesis of stromal cells in hemangioblastoma: ultrastructural and immunohistochemical study. *Ultra-struct Pathol*; 23:299-310.
 110. Marusyk A, Tabassum DP, Altrock PM, et al. (2014). Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. *Nature*; 514(7520):54-58.
 111. Aplan PD, Nakahara K, Orkin SH, et al. (1992). The SCL gene product: a positive regulator of erythroid differentiation. *EMBO J*; 11(11):4073-4081.
 112. Sinclair AM, Gottgens B, Barton LM, et al. (1999). Distinct 5V SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. *Dev Biol*; 209:128-142.
 113. Gläsker S, Li J, Xia JB, et al. (2006). Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. *Cancer Res*; 66(8): 4167-4172.
 114. Vortmeyer AO, Frank S, Jeong SY, et al. (2003). Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. *Cancer Res*; 63: 7051-7055.
 115. Lee R, Kertesz N, Joseph SB, et al. (2001). Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis. *Blood*; 98:1408-1415.
 116. Yamakawa M, Liu LX, Date T, et al. (2003). Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. *Circ Res*; 93: 664-673.
 117. Bos R, van Diest PJ, de Jong JS, et al. (2005). Hypoxia-inducible factor-1 alpha is associated with angiogenesis, and expression of Bf GF, PDGF-BB, and EGFR in invasive breast cancer. *Histopathology*; 46:31-36.
 118. Reifenberger G, Reifenberger J, Bilzer T, et al. (1995). Coexpression of transforming growth factor alpha and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. *Am J Pathol*; 147:245-250.
 119. Wizigmann-Voos S, Breier G, Risau W, et al. (1995) Upregulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. *Cancer Res*; 55: 1358-1364.
 120. Zagzag D, Krishnamachary B, Yee H, et al. (2005). Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. *Cancer Res*; 65: 6178-6188.
 121. Mitsutake N, Namba H, Takahara K, et al. (2002). Tie-2 and angiopoietin-1 expression in human thyroid tumors. *Thyroid*; 12:95-99.
 122. Mehrian-Shai R, Yalon M, Moshe I, et al. (2016). Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray Highlights novel candidate genes and pathways for pathogenesis. *BMC Genomics*; 17:56.
 123. Wang Q, Liu W, Zhang S, et al. (2021). Combined transcriptomic and lipidomic analysis reveals aberrant lipid metabolism in central nervous system hemangioblastomas. *Sci Rep*; 11(1): 1314.
 124. Vortmeyer AO, Gnarr JR, Emmert-Buck MR, et al. (1997). von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. *Hum Pathol*; 28: 540-543.
 125. Iliopoulos O, Levy AP, Jiang C, et al. (1996). Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. *Proc Natl Acad Sci USA*. 1996; 93(20): 10595-10599.
 126. Thomas RK, Nickerson E, Simons JF, et al. (2006). Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picolitre reactor sequencing. *Nat Med*; 12(7): 852-855.
 127. Arreola A, Beth Payne L, Julian MH, et al. (2018). Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. *JCI Insight*; 3(4): e2193.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

Submit Manuscript

DOI:10.31579/2642-973X/168

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/brain-and-neurological-disorders>